Navigation Links
A sticky business -- how cancer cells become more 'gloopy' as they die
Date:3/15/2009

The viscosity, or 'gloopiness', of different parts of cancer cells increases dramatically when they are blasted with light-activated cancer drugs, according to new images that provide fundamental insights into how cancer cells die, published in Nature Chemistry today (15 March).

The images reveal the physical changes that occur inside cancer cells whilst they are dying as a result of Photodynamic Therapy (PDT). This cancer treatment uses light to activate a drug that creates a short-lived toxic type of oxygen, called singlet oxygen, which kills cancerous cells.

The research team behind the study says that revealing what happens to viscosity within a dying cancer cell is important because it helps give a better understanding of how cells function and which factors are important for controlling reactions inside cells. Ultimately this could help scientists design more efficient drugs for Photodynamic Therapy and other treatments.

The research is also of wider significance because these are the first ever real-time maps showing viscosity changing over a period of time inside a cell during a biologically important process like cell death.

Previous studies have shown that the viscosity of human cells and organs also changes in patients with diseases including diabetes and atherosclerosis, says lead author Dr Marina Kuimova from Imperial College London's Department of Chemistry.

She explains: "We're still not quite sure exactly what the relationship is between increased stickiness inside cells and disease, but we expect that the two are related."

"Knowing more about these changes, and being able to map them when they occur in all kinds of different scenarios, from dying cancer cells, to diseased blood cells, could help us to better understand how some diseases and their treatments affect cell and organ function."

Dr Kuimova and her colleagues were able to track viscosity as it changed inside live cancer cells thanks to a newly-developed Photodynamic Therapy drug, with unusual fluorescent properties. The drug, which is made of a molecule with a spinning component like a rotor, emits different wavelengths of light depending on the viscosity of its surroundings.

The changing wavelengths of light emitted during experiments, and captured over a period of 10 minutes, showed that once the PDT drug was activated, the level of viscosity inside the cell increased dramatically. The researchers suggest that this increasing 'gloopiness' is caused by the toxic oxygen molecules released into the cell. They think that increased levels of viscosity might even contribute directly to the cancer cell's further deterioration by slowing down vital communication and transport processes inside the cell.

Dr Stanley Botchway from the Science and Technology Facilities Council which worked in collaboration with Imperial College London on this research, said: "The huge viscosity we measured was surprising and it certainly gives a new insight into the change in cellular environment during cell death."

However, the researchers noted that as viscosity in the cancerous cell increases, the toxic oxygen molecule's mission to kill the cell is slowed down too.

Dr Kuimova explains: "It looks like whilst the increasing viscosity contributes to the cell's demise, these new 'sticky' cell conditions can slow the drug down too, so it's not as straightforward a relationship as it might first appear.

"More work is needed to better understand the complex interplay between viscosity and cell death. We hope to use our imaging technique to track changes in viscosity in other kinds of cells as they occur in real-time, to unlock some of the secrets of what goes on inside cells when they're functioning, malfunctioning or dying."


'/>"/>

Contact: Danielle Reeves
danielle.reeves@imperial.ac.uk
44-020-759-42198
Imperial College London
Source:Eurekalert

Related biology news :

1. As sticky as a gecko... but 10 times stronger!
2. Sticky questions tackled in gecko research
3. David Rose to present Howe School lecture on new technologies and business models, Jan. 29
4. Entrepreneurs wanted for NJIT workshops about how to launch a business
5. SAFRAN to Acquire Motorolas Biometrics Business
6. Fujitsu Scanners Selected as Editors Choice in Better Buys for Business 2008 Scan-to-File Guide
7. L-1 Identity Solutions Completes Acquisition of the ID Systems Business from Digimarc Corporation
8. Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarcs ID Systems Business
9. Network science for eternal happiness and good business
10. DHS, business leaders discuss technology to protect US at Homeland Security conference
11. Adding up business and energy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: